SEC Tracker
Get the app

NextCure NXTC

NextCure FY 2020: revenue $22.4M; diluted EPS −$16.63

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers NextCure reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$22.4MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$36.6MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$16.63No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.3310-K income statement, on EDGAR
  4. Cash and cash equivalents$32.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$45.0MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when NextCure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
  2. Synergy CHC SNYR public float $13M, Jun 30, 2025
  3. Cypherpunk Technologies CYPH public float $12M, Jun 30, 2025
  4. Earth Science Tech ETST public float $14M, Mar 31, 2026
  5. Cocrystal Pharma COCP public float $12M, Jun 30, 2025